Wednesday, July 13, 2016

BioPlus Specialty Pharmacy Now Dispensing New Hepatitis C One-Pill Combination: Epclusa

One of the nation's leading innovative specialty pharmacies, BioPlus Specialty Pharmacy, is providing the newly approved combination Epclusa® (sofosbuvir/velpatasvir) to treat all genotypes of hepatitis C.

Altamonte Springs, FL (PRWEB) July 12, 2016

BioPlus Specialty Pharmacy (BioPlus), one of the nation's leading innovative specialty pharmacies, announces it is now dispensing Epclusa® (sofosbuvir/velpatasvir). Epclusa, a one-pill, once daily combination of Sovaldi® (sofosbuvir) with a new NS5A inhibitor called velpatasvir manufactured by Gilead, was approved by the U.S. Food and Drug Administration on June 28, 2016 after a priority review of its New Drug Application. It is approved to treat adult patients with hepatitis C, both with and without cirrhosis.

Epclusa's approval was supported by a series of four clinical trials demonstrating excellent safety and efficacy during 12-week treatment courses. Two of these studies indicated a 97-100% cure rate (measured by sustained virologic response) in patients with genotypes 1a, 1b, 2, 4, 5, or 6. Patients with the difficult-to-treat genotype 3 reached 95% sustained virologic response. Genotype 3 accounts for about 20% of hepatitis C cases in the U.S. Patients with cirrhosis or previous treatment failure were found to achieve sustained virologic responses of 89-91%. Few serious adverse effects were noted (16-19%), generally headache and fatigue.

"There are six genotypes of the hepatitis C virus. Prior hepatitis C medications generally only treated one or a few of these genotypes. One of the exciting things for prescribers and patients about Epclusa is that it's approved to treat all six genotypes," says Sharon Ferrer, VP of Pharmaceutical Relations at BioPlus. "In addition, the low cost (wholesale acquisition cost of $74,760) comes in at nearly 50% lower than previous treatments available for the difficult-to-treat genotype 3 of hepatitis C virus."

No comments:

Post a Comment